T-cell receptor beta chain (TCRB)

The T-cell receptor (TCR) beta chain is a critical structural component of the heterodimeric TCR complex, which is expressed on the surface of most T lymphocytes. It functions primarily in the recognition of specific antigenic peptides presented by Major Histocompatibility Complex (MHC) molecules, a process essential for the initiation of the adaptive immune response (UniProt). The beta chain is formed through somatic V(D)J recombination, contributing to the vast diversity of the TCR repertoire necessary for identifying diverse pathogens and malignant cells (NIH). When the TCR beta chain binds to its cognate antigen-MHC complex, it triggers a signaling cascade via the associated CD3 complex, leading to T-cell activation, proliferation, and the deployment of effector functions (PubMed). In modern oncology, the TCR beta chain is a primary focus for T-cell receptor-engineered (TCR-T) therapies, where TCRs are modified to target specific tumor antigens like MAGE-A4 or NY-ESO-1 (Nature). Additionally, monoclonal antibodies and bispecific T-cell engagers (BiTEs) often target the TCR-CD3 complex to redirect T-cell activity against hematological and solid tumors (StatPearls). Beyond cancer, the clonal expansion of specific TCR beta sequences is a hallmark of many autoimmune diseases and T-cell malignancies, making it both a therapeutic target and a valuable biomarker for monitoring immune health and disease progression (PubMed).

Other names

TCR-betaTRBT cell receptor beta locusT-cell antigen receptor beta polypeptideTRBC1TRBC2

Drugs targeting the T-cell receptor beta chain or its associated complex typically act as agonists to induce T-cell mediated cytotoxicity against tumor cells (in TCR-T therapies) or as modulators/antagonists to suppress auto-reactive T-cell responses in autoimmune conditions (PubMed, NIH).